Zoi Tsourti

2.0k total citations
27 papers, 1.0k citations indexed

About

Zoi Tsourti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Zoi Tsourti has authored 27 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Immunology. Recurrent topics in Zoi Tsourti's work include Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Immunotherapy and Immune Responses (5 papers). Zoi Tsourti is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Immunotherapy and Immune Responses (5 papers). Zoi Tsourti collaborates with scholars based in Greece, Switzerland and Spain. Zoi Tsourti's co-authors include Urania Dafni, Solange Peters, Katerina Vervita, Rolf A. Stahel, Enriqueta Felip, John B.A.G. Haanen, U. Dafni, George Coukos, Silvia Martin Lluesma and Heidi Roschitzki‐Voser and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Zoi Tsourti

27 papers receiving 1.0k citations

Peers

Zoi Tsourti
Mudit Chowdhary United States
Bassel Nazha United States
Christopher A. Smith United Kingdom
Janice Tsang Hong Kong
Thomas Haas United States
Michael E. Carney United States
Lindsay M. Kuroki United States
Mudit Chowdhary United States
Zoi Tsourti
Citations per year, relative to Zoi Tsourti Zoi Tsourti (= 1×) peers Mudit Chowdhary

Countries citing papers authored by Zoi Tsourti

Since Specialization
Citations

This map shows the geographic impact of Zoi Tsourti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zoi Tsourti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zoi Tsourti more than expected).

Fields of papers citing papers by Zoi Tsourti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zoi Tsourti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zoi Tsourti. The network helps show where Zoi Tsourti may publish in the future.

Co-authorship network of co-authors of Zoi Tsourti

This figure shows the co-authorship network connecting the top 25 collaborators of Zoi Tsourti. A scholar is included among the top collaborators of Zoi Tsourti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zoi Tsourti. Zoi Tsourti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lluesma, Silvia Martin, Urania Dafni, Katerina Vervita, et al.. (2025). Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals of Oncology. 36(8). 909–919. 3 indexed citations
2.
Lluesma, Silvia Martin, Inge Marie Svane, Urania Dafni, et al.. (2024). Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis. Annals of Oncology. 35(10). 860–872. 19 indexed citations
4.
Banna, Giuseppe Luigi, Alfredo Addeo, Panagiota Zygoura, et al.. (2022). A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial. Lung Cancer. 169. 77–83. 2 indexed citations
5.
Marta, Guilherme Nader, Véronique Debien, Daniel Eiger, et al.. (2022). Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study. British Journal of Cancer. 127(10). 1799–1807. 1 indexed citations
6.
Meylan, Sylvain, Urania Dafni, Frédéric Lamoth, et al.. (2021). SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. BMJ Open. 11(7). e049232–e049232. 8 indexed citations
8.
Dafni, U., Silvia Martin Lluesma, Klara Balint, et al.. (2020). Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis. European Journal of Cancer. 142. 63–82. 29 indexed citations
9.
Dziadziuszko, Rafał, Egbert F. Smit, Urania Dafni, et al.. (2019). Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Journal of Thoracic Oncology. 14(6). 1086–1094. 107 indexed citations
10.
Dafni, Urania, et al.. (2019). Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries. Breast Care. 14(6). 344–353. 137 indexed citations
11.
Dafni, Urania, Zoi Tsourti, Katerina Vervita, & Solange Peters. (2019). Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer. 134. 127–140. 160 indexed citations
12.
Dafni, U., Olivier Michielin, Silvia Martin Lluesma, et al.. (2019). Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals of Oncology. 30(12). 1902–1913. 174 indexed citations
13.
Dafni, Urania, Dirk Arnold, Susana Banerjee, et al.. (2018). Report on the status of women occupying leadership roles in oncology. ESMO Open. 3(6). e000423–e000423. 33 indexed citations
14.
Bellali, Thalia, et al.. (2018). Psychometric Properties of the Revised Death Attitude Profile in a Greek Sample of Nurses. Journal of Nursing Measurement. 26(2). 264–277. 8 indexed citations
15.
Banerjee, Susana, Urania Dafni, Dirk Arnold, et al.. (2018). Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. ESMO Open. 3(6). e000422–e000422. 50 indexed citations
16.
Homicskó, Krisztián, Georg Richtig, Felix Tuchmann, et al.. (2018). Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients. Annals of Oncology. 29. x40–x40. 29 indexed citations
17.
Voumvourakis, Konstantinos, et al.. (2014). Validity and reliability of the Greek version of the Modified Fatigue Impact Scale in multiple sclerosis patients. International Journal of Rehabilitation Research. 37(3). 271–276. 34 indexed citations
18.
Dafni, Urania, et al.. (2004). Algorithm for Statistical Detection of Peaks - Syndromic Surveillance System for the Athens 2004 Olympic Games. PsycEXTRA Dataset. 53. 86–94. 36 indexed citations
19.
Tsourti, Zoi, et al.. (2003). Extreme Value Index Estimators and Smoothing Alternatives: A Critical Review. Munich Personal RePEc Archive (Munich University). 2 indexed citations
20.
Tsourti, Zoi, et al.. (2001). A Simulation Study on the Performance of Extreme-Value Index Estimators and Proposed Robustifying Modifications. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026